ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer
European Journal of Pharmacology · 2026-01 · 1011 · 178448
DOI: 10.1016/j.ejphar.2025.178448 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026-01. Verfasst von Peipei Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Bengbu Medical University, Bengbu, China; Department of Pediatrics, First Affiliated Hospital of Bengbu Medical University, Bengb…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Fluorouracil, Autophagy, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anhui Province Excellent Young Talents Fund Program of Higher Education Institutions.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) is frequently overexpressed in colorectal cancer (CRC) and promotes tumor invasion and metastasis. Although 5-fluorouracil (5-FU) serves as a first-line CRC therapeutic, its clinical utility is constrained by dose-dependent toxicity. This study demonstrated that combining 5-FU with the EGFR inhibitor aumolertinib (AUM) synergistically suppressed CRC progression while reducing effective 5-FU doses. Transcriptomic and functional analyses linked this synergy to cellular senescence and autophagic flux blockade. Mechanistically, reactive oxygen species (ROS) accumulation drives senescence and autophagy inhibition, which inactivates the PI3K/AKT/mTOR pathway, thereby inhibiting CRC cell proliferation, invasion, and migration. Notably, ROS scavenging with N-acetylcysteine reversed these effects. The synergistic tumor growth inhibition was confirmed in HCT116 xenografts using low-dose combination therapy (5-FU 15 mg/kg + AUM 10 mg/kg). Collectively, these findings establish an ROS-dependent autophagic senescence axis as the molecular basis for 5-FU/AUM synergy, offering a novel strategic approach for CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Bengbu Medical University, Bengbu, China; Department of Pediatrics, First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Chemotherapy Department of the First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- School of Pharmacy, Bengbu Medical University, Bengbu, China.
- School of Pharmacy, Bengbu Medical University, Bengbu, China; Anhui Province Engineering Technology Research Center of Biochemical Pharmaceutical, Bengbu, China.
- Department of Gastroenterology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Emergency Surgery Department of the First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Electronic address: 13855208940@163.com.
Förderung
- Anhui Province Excellent Young Talents Fund Program of Higher Education Institutions
Zitieren
APA
Liu, P., Wu, X., Jiang, Z., Zhang, P., Meng, Z., Xu, C., Ao, D., Jiang, J., & Liu, H. (2026). ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer. European Journal of Pharmacology, 1011, 178448. https://doi.org/10.1016/j.ejphar.2025.178448
Vancouver
Liu P, Wu X, Jiang Z, Zhang P, Meng Z, Xu C, et al. ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer. European Journal of Pharmacology. 2026;1011:178448. doi:10.1016/j.ejphar.2025.178448
BibTeX
@article{Liu2026,
author = {Liu, Peipei and Wu, Xiao and Jiang, Zuojie and Zhang, Pei and Meng, Zixuan and Xu, Chenming and Ao, Di and Jiang, Jing and Liu, Hao},
title = {ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer},
journal = {European Journal of Pharmacology},
year = {2026},
volume = {1011},
pages = {178448},
doi = {10.1016/j.ejphar.2025.178448}
}
EUVIMED